

**Form 604**Corporations Act 2001  
Section 671B**Notice of change of interests of substantial holder**To Company Name/Scheme Viralytics LimitedACN/ARSN 010 657 351**1. Details of substantial holder(1)**Name Cormorant Global Healthcare Master Fund, LP, and their associates in Annexure A

ACN/ARSN (if applicable) \_\_\_\_\_

There was a change in the interests of the substantial holder on 15/12/2015, 04/05/2016, 11/10/2016, 12/10/2016, 13/10/2016, 14/10/2016, 18/10/2016, 19/10/2016, 20/10/2016, 14/07/2017The previous notice was given to the company on 14 / 03 / 2014The previous notice was dated 14 / 03 / 2014**2. Previous and present voting power**

The total number of votes attached to all the voting shares in the company or voting interests in the scheme that the substantial holder or an associate (2) had a relevant interest (3) in when last required, and when now required, to give a substantial holding notice to the company or scheme, are as follows:

| Class of securities(4)     | Previous notice |                 | Present notice |                 |
|----------------------------|-----------------|-----------------|----------------|-----------------|
|                            | Person's votes  | Voting power(5) | Person's votes | Voting power(5) |
| Fully paid ordinary shares | 16,420,361      | 8.9%            | 18,091,987     | 7.49%           |

**3. Changes in relevant interests**

Particulars of each change in, or change in the nature of, a relevant interest of the substantial holder or an associate in voting securities of the company or scheme, since the substantial holder was last required to give a substantial holding notice to the company or scheme are as follows:

| Date of change   | Person whose relevant interest changed      | Nature of change (6)   | Consideration given in relation to change (7) | Class and number of securities affected | Person's votes affected |
|------------------|---|--|---|---|-------------------------|
| 15 December 2015 | Cormorant Global Healthcare Master Fund, LP | Participation in the company's secondary offering                                | \$ 2,537,284.90                               | 4,092,395 fully paid ordinary shares    | 4,092,395               |
| 4 May 2016       | CRMA SPV, L.P.                              | On Market purchase and transfer from Cormorant Global Healthcare Master Fund, LP | \$ 193,568.76                                 | 251,388 fully paid ordinary shares      | 3,482,147               |
| 11 October 2016  | Cormorant Global Healthcare Master Fund, LP | On Market purchase   | \$25,992.95                                   | 27,361 fully paid ordinary shares       | 27,361                  |
| 11 October 2016  | CRMA SPV, L.P.                              | On Market purchase   | \$5,267.75                                    | 5,545 fully paid ordinary shares        | 5,545                   |
| 12 October 2016  | Cormorant Global Healthcare Master Fund, LP | On Market purchase   | \$40,198.00                                   | 40,198 fully paid ordinary shares       | 40,198                  |
| 12 October 2016  | CRMA SPV, L.P.                              | On Market purchase   | \$8,146.00                                    | 8,146 fully paid ordinary shares        | 8,146                   |

| Date of change  | Person whose relevant interest changed      | Nature of change (6) | Consideration given in relation to change (7) | Class and number of securities affected | Person's votes affected |
|-----------------|---|----------------------|---|---|-------------------------|
| 13 October 2016 | Cormorant Global Healthcare Master Fund, LP | On Market purchase   | \$672,111.42                                  | 550,911 fully paid ordinary shares      | 550,911                 |
| 13 October 2016 | CRMA SPV, L.P.                              | On Market purchase   | \$136,200.80                                  | 111,640 fully paid ordinary shares      | 111, 640                |
| 14 October 2016 | Cormorant Global Healthcare Master Fund, LP | On Market purchase   | \$226,160.10                                  | 183,870 fully paid ordinary shares      | 183, 870                |
| 14 October 2016 | CRMA SPV, L.P.                              | On Market purchase   | \$45,829.80                                   | 37,260 fully paid ordinary shares       | 37, 260                 |
| 18 October 2016 | Cormorant Global Healthcare Master Fund, LP | On Market purchase   | \$61,720.00                                   | 49,376 fully paid ordinary shares       | 49,376                  |
| 18 October 2016 | CRMA SPV, L.P.                              | On Market purchase   | \$12,507.50                                   | 10,006 fully paid ordinary shares       | 10,006                  |
| 19 October 2016 | Cormorant Global Healthcare Master Fund, LP | On Market purchase   | \$81,457.98                                   | 66,266 fully paid ordinary shares       | 66,266                  |
| 19 October 2016 | CRMA SPV, L.P.                              | On Market purchase   | \$16,506.60                                   | 13,420 fully paid ordinary shares       | 13,420                  |
| 20 October 2016 | Cormorant Global Healthcare Master Fund, LP | On Market purchase   | \$16,726.20                                   | 13,710 fully paid ordinary shares       | 13,710                  |
| 20 October 2016 | CRMA SPV, L.P.                              | On Market purchase   | \$3,390.38                                    | 2,779 fully paid ordinary shares        | 2,779                   |
| 14 July 2017    | Cormorant Global Healthcare Master Fund, LP | On Market sale       | \$3,087,697.92                                | 3,216,352 fully paid ordinary shares    | 3,216,352               |
| 14 July 2017    | CRMA SPV, L.P.                              | On Market sale       | \$622,322.88                                  | 648,253 fully paid ordinary shares      | 648,253                 |

#### 4. Present relevant interests

Particulars of each relevant interest of the substantial holder in voting securities after the change are as follows:

| Holder of relevant interest     | Registered holder of securities             | Person entitled to be registered as holder (8) | Nature of relevant interest (6)  | Class and number of securities | Person's votes |
|---------------------------------|---|--|--|--------------------------------|----------------|
| Cormorant Asset Management, LLC | Cormorant Global Healthcare Master Fund, LP | Cormorant Global Healthcare Master Fund, LP    | Relevant interest arises under Sections 608(1)(b) and (c) of the Corporations Act of 2001, by virtue of Cormorant Asset Management, LLC acting as investment manager of the registered holder of securities whereby it holds the authority dispose of the securities, and cast votes in respect of the securities. | 14,997,297                     | 14,997,297     |

|  |                |                |   |           |           |
|--|----------------|----------------|---|-----------|-----------|
| Cormorant<br>Asset<br>Management,<br>LLC | CRMA SPV, L.P. | CRMA SPV, L.P. | Relevant interest arises under Sections 608(1)(b) and (c) of the Corporations Act of 2001, by virtue of Cormorant Asset Management, LLC acting as investment manager of the registered holder of securities whereby it holds the authority dispose of the securities, and cast votes in respect of the securities | 3,002,690 | 3,002,690 |
|--|----------------|----------------|---|-----------|-----------|

**5. Changes in association**

The persons who have become associates (2) of, ceased to be associates of, or have changed the nature of their association (9) with, the substantial holder in relation to voting interests in the company or scheme are as follows:

| Name and ACN/ARSN (if applicable) | Nature of association  |
|-----------------------------------|--|
| CRMA SPV, L.P.                    | CRMA SVP, L.P.'s investment mandate is identical to that of Cormorant Global Healthcare Master Fund, LP and is conducted by the same investment manager, Cormorant Asset Management, LLC |

**6. Addresses**

The addresses of persons named in this form are as follows:

| Name  | Address   |
|---|---|
| Cormorant Global Healthcare Master Fund, LP | 200 Clarendon St, 52 <sup>nd</sup> Floor, Boston, MA 02116, USA |
| CRMA SPV, L.P.                              | PO Box 309, Ugland House, Grand Cayman; KY1-1104 Cayman Islands |

**Signature**

print name Neb Obradovic

capacity CCO

sign here

date July 26, 2017

**DIRECTIONS**

- (1) If there are a number of substantial holders with similar or related relevant interests (eg a corporation and its related corporations, or the manager and trustee of an equity trust), the names could be included in an annex to the form. If the relevant interests of a group of persons are essentially similar, they may be referred to throughout the form as a specifically named group if the membership of each group, with the names and addresses of members is clearly set out in paragraph 6 of the form.
- (2) See the definition of "associate" in section 9 of the Corporations Act 2001
- (3) See the definition of "relevant interest" in sections 608 and 671B(7) of the Corporations Act 2001
- (4) The voting shares of a company constitute one class unless divided into separate classes
- (5) The person's votes divided by the total votes in the body corporate or scheme multiplied by 100
- (6) Included details of:
  - (a) any relevant agreement or other circumstances because of which the change in relevant interest occurred. If subsection 671B(4) applies, a copy of any document setting out the terms of any relevant agreement, and a statement by the person giving full and accurate details of any contract, scheme or arrangement, must accompany this form, together with a written statement certifying this contract, scheme or arrangement; and
  - (b) any qualification of the power of a person to exercise, control the exercise of, or influence the exercise of, the voting powers or disposal of the securities to which the relevant interest relates (indicating clearly the particular securities to which the qualification applies)

See the definition of "relevant agreement" in section 9 of the Corporations Act 2001
- (7) Details of the consideration must include any and all benefits, money and other, that any person from whom a relevant interest was acquired has, or may, become entitled to receive in relation to that acquisition. Details must be included even if the benefit is conditional on the happening or not of a contingency. Details must be included of any benefit paid on behalf of the substantial holder or its associate in relation to the acquisitions, even if they are not paid directly to the person from whom the relevant interest was acquired.
- (8) If the substantial holder is unable to determine the identity of the person (eg if the relevant interest arises because of an option) write "unknown".
- (9) Give details, if appropriate, of the present association and any change in that association since the last substantial holding notice.

This is Annexure "A" of 1 page referred to in the Form 604 signed by me and dated  
July 26, 2017



Name Neb Obradovic

Position CCO

July 26, 2017

Associates of the substantial holder are as follows:

| Name and ACN/ARSN (if applicable) | Nature of association  |
|-----------------------------------|--|
| CRMA SPV, L.P.                    | CRMA SVP, L.P.'s investment mandate is identical to that of Cormorant Global Healthcare Master Fund, LP and is conducted by the same investment manager, Cormorant Asset Management, LLC |